Dr. Saulez and fellow researchers recently published a manuscript entitled: “Coagulation, oncotic and haemodilutional effects of a 3rd generation hydroxyethyl starch (130/0.4) solution in horses”. Colloids are used for rapid plasma volume expansion and oncotic support during periods of hypoproteinaemia. However, side effects associated with colloid administration such as coagulopathies limit veterinary use. During this trial, Voluven® was administered to 6 healthy pony mares at 10, 20 and 40ml/kg body weight with a 2-week washout period. Packed cell volume, plasma total solids, colloid osmotic pressure (COP), platelet count and thromboelastography (TEG) were measured at baseline, immediately after infusion (0 hours), and 1, 6, 12, 24, 48 and 96 hours after Voluven® infusion.
Results show that all TEG variables remained within normal reference ranges in all 3 treatment groups. Administration of Voluven® at 40 ml/kg body weight resulted in a prolonged K-time (P = 0.049) at 6 hours post infusion, and decreased maximum amplitude at 0 (P<0.001), 1 (P=0.022), 6 (P=0.006), 24 (P<0.001) and 48 hours (P=0.013) post infusion compared with baseline. Administration of Voluven® increased mean COP values above baseline in all 3 treatment groups, persisting to 24, 6 and 48 hours for the 10, 20 and 40 ml/kg body weight doses, respectively. The study concluded that although still within established reference ranges, compared with lower dosages, the administration of 40 ml/kg body weight Voluven® was more likely to induce changes in coagulation as measured by TEG. Voluven® safely increased COP at all dosages evaluated in healthy horses. Voluven® administered at 10 and 20 ml/kg body weight has potential as a synthetic colloid for resuscitation and provision of oncotic support in horses.
Download full report.